The incidence and patient outcomes of Staphylococcus aureus isolates by iclaprim MIC was determined among patients from two phase 3 studies for the treatment of acute bacterial skin and skin structure infections (ABSSSI), REVIVE-1 and -2. Iclaprim MIC90 values were 0.12 µg ml-1 for S. aureus (0.12 µg ml-1 against methicillin-sensitive and 0.25 µg ml-1 against methicillin-resistant S. aureus). The incidence of culture confirmed S. aureus isolates among patients with ABSSSI with an iclaprim MIC > 8 µg ml-1 was 2.0 % (16/790). The clinical outcomes varied by MICs for early clinical response (63-100 %), end of therapy response (81-100 %) and the test of cure response (75-100 %). For microbiological outcomes of these infections, the end of therapy response was 80-100 % and the test of cure response was 88-100 %.
Keywords: Staphylococcus aureus; iclaprim; incidence; resistance; skin infections.